NCT00762463

Study Of Celecoxib Or Diclofenac For Efficacy and Safety In Chinese Patients With Ankylosing Spondylitis

A 6-Week, Randomized, Double-Blind, Parallel-Group Study To Evaluate The Symptomatic Effects And Safety Of Celecoxib 200mg QD Compared To Diclofenac 75mg SR QD In Chinese Patients With Ankylosing Spondylitis, With 6-Week Extension Phase Treatment On Celecoxib 400 Mg QD Or Maintaining Double-Blind Phase Therapy

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 240 (actual)
• Sponsor: Pfizer's Upjohn has merged with Mylan to form Viatris Inc. · Industry
• Sex: All
• Age: 18 Years – 65 Years
• Healthy volunteers: Not accepted

Summary

This is a local, multicenter, randomized, active comparator, double-blind, parallel group study with extension will be conducted to evaluate the efficacy and safety of celecoxib versus diclofenac SR in the treatment of Chinese patients with Ankylosing Spondylitis (AS).

Conditions

• Ankylosing Spondylitis

Interventions

Type	Name	Description
DRUG	Celecoxib	capsule, 200 mg QD, 6-12 weeks
DRUG	Diclofenac SR	tablet, 75 mg QD,6-12 weeks

Timeline

• Start date: 2009-07-01
• Primary completion: 2010-06-01
• Completion: 2010-08-01
• First posted: 2008-09-30
• Last updated: 2021-02-02
• Results posted: 2011-08-23

Locations

5 sites across 1 country: China